Home Liquid Biopsy and ctDNA ESR1 Liquid Biopsy Test: Breast Cancer Hormone Resistance Marker and ctDNA Monitoring

ESR1 Liquid Biopsy Test: Breast Cancer Hormone Resistance Marker and ctDNA Monitoring

By
Vita Library
-
4
Learn what an ESR1 liquid biopsy detects, how positive and negative ctDNA results are interpreted, and how emerging ESR1 mutations can guide advanced breast cancer therapy.

An ESR1 liquid biopsy checks circulating tumor DNA (ctDNA) in blood for mutations in the gene that encodes estrogen receptor alpha. In estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer, ESR1 mutations often emerge during treatment with aromatase inhibitors and can become an important sign of endocrine resistance. Detecting the mutation can now directly influence treatment because several estrogen-receptor-directed therapies have FDA indications tied to ESR1 status, and one current strategy uses serial ctDNA testing to identify an emerging ESR1 mutation before radiographic progression.

A positive result does not mean all hormone therapy has stopped working. It means the cancer has acquired a molecular change that can reduce sensitivity to estrogen-deprivation approaches, especially aromatase inhibitors. A negative result is also not absolute: ctDNA can be too low to detect, and the mutation can emerge later under treatment pressure. The result should therefore be interpreted with current therapy, disease status, assay coverage, and timing.

  • A positive ESR1 ctDNA result usually indicates an acquired estrogen-receptor mutation associated with resistance to aromatase-inhibitor therapy in advanced ER-positive breast cancer.
  • ESR1 mutations are treatment biomarkers, not a blood “level”; reports usually list specific variants such as Y537, D538, E380, or other covered mutations rather than a normal range.
  • A negative blood test does not permanently rule out ESR1 mutation because low ctDNA can cause false negatives and the mutation may develop later during endocrine therapy.
  • Current ESR1-directed options include therapies with FDA indications based on an FDA-authorized mutation test; the exact drug choice depends on treatment line and current labeling.
  • Serial ESR1 ctDNA testing can be clinically meaningful in selected patients because emerging mutations may be detected before imaging shows progression.

Table of Contents

What ESR1 Mutations Mean

The ESR1 gene provides instructions for estrogen receptor alpha, the main estrogen receptor that drives growth in many hormone receptor-positive breast cancers. Standard endocrine treatments interfere with this pathway in different ways. Aromatase inhibitors lower estrogen production; selective estrogen receptor modulators change receptor signaling; and selective estrogen receptor degraders or other ER-targeted drugs reduce or disrupt receptor activity.

In many ER-positive cancers, the tumor begins without a detectable ESR1 mutation. Under the selective pressure of endocrine therapy—particularly aromatase-inhibitor exposure in advanced disease—a subclone can acquire an ESR1 alteration that keeps the receptor active even when estrogen levels are very low. That is why ESR1 mutations are commonly described as acquired endocrine-resistance mutations.

Frequently discussed variants occur in the ligand-binding domain of the receptor, including changes around codons 537 and 538. Laboratories may also report E380 and other mutations depending on assay design and the companion-diagnostic indication involved. There is no “high” or “low” ESR1 laboratory range comparable with a routine blood chemistry test. The key result is whether a clinically relevant mutation is detected and exactly which variant the assay found.

An ESR1 mutation test for breast cancer may be performed on tissue or plasma. Liquid biopsy is particularly useful because resistance can evolve after the original tumor biopsy, making an old tissue specimen biologically outdated for the current treatment question.

ESR1 mutation is not the same as estrogen-receptor positivity by immunohistochemistry. ER-positive status describes protein expression in tumor tissue. ESR1 mutation describes a DNA alteration in the receptor gene. A cancer can be ER-positive and ESR1 wild-type, or ER-positive with an acquired ESR1 mutation.

When an ESR1 Liquid Biopsy Is Used

The strongest clinical role is in ER-positive, HER2-negative advanced or metastatic breast cancer after exposure to endocrine therapy. The test can help determine whether the cancer has developed a resistance mechanism that makes certain ER-directed treatments more appropriate than continuing the same aromatase-inhibitor strategy.

Testing may be considered at progression, when a clinician is choosing the next endocrine therapy. It may also be performed during treatment before radiographic progression in a setting where serial mutation detection has a specific evidence-based treatment consequence.

Liquid biopsy offers several practical advantages:

  • it requires a blood draw rather than an invasive tumor biopsy;
  • it can be repeated as the cancer evolves;
  • it may capture DNA shed from multiple metastatic sites;
  • it can identify a mutation that was not present in archival tissue;
  • broad panels can simultaneously detect other actionable alterations such as PIK3CA changes.

A circulating tumor DNA test for breast cancer may therefore answer more than the ESR1 question. The oncology team may want a broader molecular profile because endocrine resistance can involve several pathways, and the next therapy may depend on the combination of ESR1, PIK3CA, AKT1, PTEN, germline findings, HER2 expression, and prior treatments.

Testing is usually not used to diagnose early breast cancer or to determine whether a breast mass is malignant. ESR1 liquid biopsy is a predictive and resistance biomarker test in a defined cancer context, not a general screening blood test.

The timing also differs from a one-time tumor biomarker panel performed at diagnosis. A patient can have an ESR1-wild-type result when metastatic treatment begins and develop an ESR1 mutation later while receiving an aromatase inhibitor. For that reason, an old negative result may not answer a new resistance question. The oncologist should use the most clinically relevant specimen and may prefer a fresh plasma test when the purpose is to detect treatment-emergent resistance.

Tissue remains valuable when the cancer’s phenotype may have changed, when another diagnosis is possible, or when a blood sample contains too little ctDNA. Plasma is particularly attractive for repeated monitoring because repeated metastatic biopsies are more invasive and may sample only one lesion.

How the Test Works

Blood is collected into tubes designed for cell-free DNA testing. After plasma is separated from blood cells, the laboratory extracts cfDNA. The tumor-derived portion is ctDNA. The assay then searches for predefined ESR1 mutations, often with next-generation sequencing (NGS) or another highly sensitive molecular method.

Some tests are broad comprehensive genomic profiling panels, while others focus on a smaller group of breast-cancer biomarkers. An FDA-authorized companion diagnostic has validated analytical performance for the specific treatment-selection claim in its labeling. That distinction matters because not every commercial or laboratory-developed assay covers exactly the same ESR1 variants.

The report may show:

  • the ESR1 variant detected;
  • variant allele frequency (VAF), if reported;
  • whether the finding has a companion-diagnostic association;
  • other genomic alterations found in the same sample;
  • comments about low ctDNA, test sensitivity, or a negative result;
  • suggested clinical evidence categories, which still require physician interpretation.

VAF is the fraction of sequencing reads at a particular position that carry the mutation. It is not the percentage of cancer cells in the body. A low VAF can still represent a real resistant subclone, especially when a sensitive assay detects a known ESR1 hotspot. Clonal evolution, metastatic-site shedding, copy number, and the amount of normal cfDNA all affect the number.

No fasting is generally needed unless another ordered test requires it. Sample integrity is more important. Collection, storage, and shipping must follow the testing laboratory’s validated instructions so that DNA from normal blood cells does not overwhelm the relatively small ctDNA signal.

How to Read Positive and Negative Results

A positive ESR1 liquid-biopsy result means a covered ESR1 mutation was detected in circulating DNA at or above the assay’s validated threshold. In an ER-positive, HER2-negative advanced breast cancer previously treated with endocrine therapy, that finding supports the presence of an endocrine-resistant clone.

The result does not mean endocrine therapy as a whole is useless. ESR1 mutations often reduce sensitivity to estrogen deprivation with aromatase inhibitors, while other strategies that directly antagonize or degrade the estrogen receptor can retain activity. This distinction is the reason ESR1 has become a treatment-selection biomarker rather than merely a marker of poor response.

A negative result is more complicated. It may mean:

  • the tumor is truly ESR1 wild-type at that time;
  • the mutation is present but below the test’s detection limit;
  • the cancer is shedding little ctDNA into plasma;
  • the mutation exists in a metastatic site that contributes little DNA to blood;
  • a resistance mutation has not developed yet but may emerge later.

When a broad plasma panel detects several tumor-derived alterations but no ESR1 mutation, the sample is more clearly informative than a specimen in which no tumor-associated DNA is detected at all. Even then, a later sample can become positive as treatment changes the clonal makeup of the disease.

A ctDNA tumor fraction estimate can help show whether enough tumor DNA was present for a negative genomic result to be reassuring. Low tumor fraction increases the risk of false-negative plasma findings.

Tissue testing can still be useful when the blood result is non-informative or when pathology needs reassessment. Liquid biopsy and tissue biopsy are complementary rather than mutually exclusive.

How ESR1 Results Can Change Treatment

The clinical importance of ESR1 testing has expanded rapidly. As of September 2026, multiple FDA-approved treatment strategies use ESR1 mutation status in ER-positive, HER2-negative advanced or metastatic breast cancer. The exact eligibility rules differ, so the clinician must match the mutation, treatment history, disease state, and authorized test to the current prescribing information.

Elacestrant was the first oral selective estrogen receptor degrader approved specifically for ESR1-mutated ER-positive, HER2-negative advanced or metastatic breast cancer after disease progression following at least one line of endocrine therapy. The phase III EMERALD trial established a progression-free-survival benefit in the ESR1-mutated subgroup.

Imlunestrant was FDA-approved in September 2025 for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression following at least one line of endocrine therapy. The EMBER-3 trial showed improved progression-free survival versus standard endocrine therapy in patients with ESR1 mutations.

Vepdegestrant, an oral PROTAC estrogen-receptor degrader, was FDA-approved in May 2026 for ESR1-mutated ER-positive, HER2-negative advanced or metastatic breast cancer after progression following at least one line of endocrine therapy. In VERITAC-2, the benefit versus fulvestrant was concentrated in the ESR1-mutated population.

Camizestrant received accelerated FDA approval on September 4, 2026 for a different clinical strategy: switching from an aromatase inhibitor to camizestrant while continuing a CDK4/6 inhibitor when an ESR1 mutation is detected during first-line aromatase-inhibitor plus CDK4/6 therapy, before radiographic progression. This indication reflects the SERENA-6 trial and makes serial ctDNA detection part of an active treatment-timing decision.

These approvals do not make all ESR1-positive cases interchangeable. Prior therapies, the exact mutation covered by the companion diagnostic, disease progression status, adverse-effect profile, drug interactions, menopausal status where relevant, and other tumor biomarkers all influence selection.

A broader hormone receptor-positive breast cancer biomarker profile can be important because another actionable alteration may point toward a different targeted therapy or combination.

Serial ctDNA Monitoring and Emerging Resistance

One of the most important developments in ESR1 testing is the shift from testing only after obvious progression to testing for molecular evolution during therapy.

The SERENA-6 strategy repeatedly tested ctDNA in patients receiving first-line aromatase-inhibitor plus CDK4/6-inhibitor therapy. Patients with a newly detected ESR1 mutation but no radiographic progression were randomized either to switch the aromatase inhibitor to camizestrant while continuing the CDK4/6 inhibitor or to continue the original regimen. Switching on the basis of emerging ESR1 mutation improved progression-free survival.

This is clinically different from simply drawing ctDNA frequently “to see what happens.” Serial testing is useful when the timing, assay, mutation definition, and treatment response have been validated for a specific decision. The FDA-authorized companion-diagnostic approach for camizestrant should be followed according to current labeling and oncology guidance rather than replaced by an arbitrary home schedule.

ESR1 mutations can be dynamic. A resistant clone may rise under aromatase-inhibitor pressure and later fall when therapy changes. Multiple ESR1 mutations can also coexist in the same patient. Broad plasma testing can capture this polyclonal resistance better than a single-site tissue biopsy in some cases.

A Guardant360 liquid biopsy has been used as an FDA-authorized companion diagnostic for several ESR1-directed therapies. However, the Guardant portfolio and assay labeling have changed over time, so clinicians should use the currently authorized version and its current instructions rather than relying on an older report format.

Serial VAF changes should not be interpreted as a precise percentage change in total tumor burden. Imaging, symptoms, laboratory findings, and overall disease course remain essential. The most important new principle is that a molecular resistance signal can sometimes become actionable before radiographic progression—but only in the clinical setting where evidence supports acting on it.

Limitations and Questions to Ask

Liquid biopsy can miss ESR1 mutations when ctDNA is scarce. Bone-dominant metastatic breast cancer can sometimes produce lower plasma tumor DNA than extensive visceral disease, although shedding varies greatly between individuals. A negative result from a low-shedding sample should therefore be interpreted cautiously.

Another limitation is assay coverage. Different ESR1-directed drugs may have companion-diagnostic definitions that include different mutation sets. A test that reports “ESR1 negative” must be evaluated against what variants it actually examined and what treatment is being considered.

Clonal hematopoiesis is generally a larger interpretation problem for genes commonly mutated in blood-cell clones, but all plasma genomic reports still require expert review. The laboratory and oncology team should distinguish tumor-derived findings from potential non-tumor signals using validated methods and the overall genomic pattern.

Common mistakes include treating ESR1 mutation as a hereditary finding, assuming a negative result will remain negative forever, or assuming every positive result mandates the same drug. In most advanced breast cancers, acquired ESR1 mutations are somatic tumor changes and do not by themselves indicate an inherited cancer risk.

Useful questions for the oncology visit include:

  • Which ESR1 mutation was detected, and is it covered by the treatment’s FDA-authorized companion diagnostic?
  • Was the blood sample clearly ctDNA-positive, or could a negative result be non-informative?
  • Should ESR1 be retested later if I continue an aromatase inhibitor?
  • Is the goal to switch therapy after progression or to act on an emerging mutation before imaging progression?
  • Which ESR1-directed therapies fit my prior treatment history and current disease setting?
  • Were PIK3CA, AKT1, PTEN, HER2-related, or other actionable biomarkers assessed at the same time?
  • Would tissue biopsy add information that the liquid biopsy cannot provide?

The best interpretation is therefore not simply “mutated” versus “not mutated.” It is a time-specific molecular result that can reveal how an ER-positive cancer is adapting to therapy and, in the right setting, guide a more precise next step.

References

Disclaimer

ESR1 liquid-biopsy results should be interpreted by a breast oncology team using the exact assay, mutation, treatment history, and current drug labeling. A negative plasma result does not permanently exclude an ESR1 mutation, and a positive result does not by itself determine the best therapy. Do not change endocrine or targeted treatment without guidance from the treating clinician.

RELATED ARTICLESMORE FROM AUTHOR